SubHero Banner

Cibinqo® (abrocitinib) – New drug approval

On January 14, 2022, Pfizer announced the FDA approval of Cibinqo (abrocitinib), for the treatment  of adults with refractory, moderate-to-severe atopic dermatitis (AD) whose disease is not adequately  controlled with other systemic drug products, including biologics, or when use of those therapies is  inadvisable.

Download PDF